Abstract Gall bladder cancer is a common cancer in the Ganges belt of North-eastern India. In view of incidental diagnosis of gall bladder cancer by physicians and surgeons, the treatment is not optimised. Most patients present in advanced stages and surgery remains the only option to cure. This review highlights the current evidence in advances in systemic therapy of gall bladder cancer.
Introduction
Gallbladder carcinoma (GBC) is a major cause of mortality in cancer in areas of the world where it is commonly diagnosed. The prognosis associated with GBC is poor predominantly due to advanced stage at diagnosis, which is often related to lack of or nonspecific symptoms during the early stages of disease. Surgery is the only treatment modality that provides a chance of cure. However recurrence is common in the form of distant metastasis and long term survivors are less than 30 percent [1, 2] . The incorporation of systemic chemotherapy and novel agents have been tested in many clinical trials to improve the chances of cure in resectable disease and improve survival in advanced disease.
Adjuvant Therapy

Chemotherapy
The existing literature related to the adjuvant treatment in GBC is difficult to interpret with conflicting results. Majority of data is from retrospective studies in whom GBC has been studied along with other biliary cancers.
In contrast to patients who have margin-positive surgery, in whom locoregional recurrences are common, the pattern of disease recurrence following complete resection of GBC is both local and distant . In a series of 97 patients who underwent surgery for GBC (90 percent of whom had a margin-negative surgery), locoregional disease as the first site of recurrence occurred in 15 percent of cases; an initial recurrence involving a distant site, with or without associated locoregional recurrence was seen in 85 percent [2] .s This suggests that chemotherapy could be a more rational adjuvant treatment strategy than radiotherapy (RT) or chemo radiotherapy (CRT). Retrospective series have suggested benefit from adjuvant chemotherapy [3] [4] [5] . In a multicenter trial from Japan of 140 patients comparing surgery with and without postoperative chemotherapy (two courses of mitomycin C and infusional 5-FU, followed by prolonged oral administration of 5-FU until tumor progression), 90 percent of patients who had positive lymph nodes showed a benefit from adjuvant chemotherapy. The five-year survival rate was higher in patients who were assigned to chemotherapy at random (26 versus 14 percent) [6] . Most centres where adjuvant chemotherapy is practised, use 5FU or Gemcitabine separately or in combination with a platinum where better efficacy has been seen in advanced stages [7, 8] .
Chemo-Radiotherapy and Radiation Therapy
The efficacy of adjuvant radiation therapy (RT) in the treatment of GBC is not established. After surgical resection, postoperative external beam RT can reduce local recurrence; however effect on overall survival has not been proven due to lack of good quality clinical trials. Retrospective reviews with a small sample size in which either RT alone or CRT (generally with a concomitant fluoropyrimidine) was administered have suggested better survival [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In most situations, the conclusion was that the patients who underwent RT as a part of therapy (particularly at doses ≥40 Gy) had better survival than those who did not. Table 1 summarizes the limited  available data regarding adjuvant treatment of GBC. Furthermore, most series included few patients, and many included various sites of the biliary system (GBC along with cholangiocarcinoma), making it difficult to draw rational conclusions. The benefit of adjuvant RT has been refuted by others [2, 23, 24] . It is possible that the apparent survival prolongation was due to selection of fitter patients for adjuvant therapy and tumor biology and was not related to the use of RT. Well designed randomized trials exclusively for GBC are needed to define the role of adjuvant radiotherapy in GBC.
IORT (Intraoperative Radiotherapy)
The limited radiation tolerance of normal tissues surrounding the gallbladder fossa led to the introduction of intraoperative radiation therapy (IORT), a technique that allows the delivery of a large dose of RT to the tumor alone, while excluding adjacent structures. Previous reports suggest an advantage of IORT for both palliation and cure [25] [26] [27] . In one nonrandomized series, 17 of 27 patients undergoing resection for T4N0-1 GBC received IORT with or without postoperative external beam RT [25] . The three-year cumulative survival following surgery along with IORT versus surgery alone was 10 versus 0 percent. The routine use of IORT is limited by availability of the same and the logistics of intraoperative treatment and currently should be part of a clinical trial as the numbers are too small to draw any definite conclusions.
Meta-Analysis
The benefits of adjuvant therapy following curative-intent resection for biliary tract malignancy (intra hepatic and extrahepatic bile ducts as well as GBC) were studied in a metaanalysis that included a single randomized trial of only chemotherapy [28] , two SEER registry analyses, and 17 retrospective series, comprising 6,712 patients, of whom 1797 received adjuvant therapy. To be eligible, studies had to include patients who had curative-intent surgery alone (defined as negative [R0] or microscopically positive [R1] margins) as a control group. There were eight studies of RT and chemotherapy, three of only chemotherapy, and nine of RT alone. Only five of these were conducted in GBC, one of which has been discussed above, four studied EBRT, and two with associated chemo radiotherapy.
The following were the results:
The improvement in five-year survival with any adjuvant therapy compared with surgery alone, was not statistically significant (pooled odds ratio [OR] 0.74, 95 % CI 0.55-1.01). The results were identical when gallbladder and bile duct cancers were analyzed separately. However, the survival improvement from adjuvant therapy was statistically significant when data from the two large registry series (n=1,233 patients) were excluded (OR 0.53, 95 % CI 0.39-0.72). The benefits of adjuvant treatment were modality-dependent; in a combined analysis of gallbladder and bile duct cancers, there was a significant survival benefit for chemotherapy (OR 0. Nine studies, in which at least 50 percent of the patients had margin or node positivity, were analyzed separately: Pooled data showed a statistically significant overall survival benefit for any adjuvant therapy in node-positive disease (OR 0.49, 95 % CI 0.30-0.80). Most of these patients (77 percent) had received only chemotherapy, while the remainder underwent CRT [28] . Also, similar to node positive disease, a significant advantage for any adjuvant therapy was shown in patients with margin-positive disease (OR 0.36, 95 % CI 0.19-0.68). About two-thirds of the treated R1 patients (63 percent) had received only RT as a component of adjuvant therapy, while the majority of R0 studies used chemo radiotherapy, and most of these included patients who were node-positive. Following a R1 resection, there was a statistically significant advantage from adjuvant RT (OR 0.33, 95 % CI 0.14-0.81), while after R0 resection, adjuvant RT alone was associated with a worse survival (OR 1.26, 95 % CI 0.88-1.79). However, since most of the patients with R0 disease had positive nodes and received a combination of chemotherapy and RT, the analogy is not well matched.
There was limited data to evaluate the benefit of chemotherapy in patients with node-negative disease. In an exploratory analysis, the benefit of adjuvant chemotherapy was greater in studies in which at least 50 percent of the patients had nodepositive or R1 disease or both, compared to studies that did not include many patients with node-positive or R1 disease.
While this analysis validates the benefit of adjuvant therapy for high-risk subgroups with GBC, it does not resolve the issue of the best treatment strategy (i.e., chemo radiotherapy versus chemotherapy alone) for high-risk patients, or fully address the advantage of adjuvant therapy for low-risk patients (i.e., node-negative). Randomized trials are urgently needed in this area.
Prediction Models
One group of authors attempted to construct a prediction model for estimating the survival advantage of adjuvant RT based on 4,180 patients with resected GBC who were reported to the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) records between 1988 and 2003. Adjuvant RT was administered to 760 patients; the number who also received concomitant chemotherapy was not reported. In a multivariate analysis, male sex, older age, nonpapillary histology, and no adjuvant RT were important predictors of overall worse survival. Clinicopathological features were then used to construct a nomogram (available online) which predicted survival both with and without RT [29] . The authors reported that patients with ≥ T2 stage, node-positive disease derived the greatest advantage from RT. However, as noted above, it is possible that the apparent survival prolongation from RT seen in this series was due to patient selection and/or tumor biology, and not due to RT.
In order to ascertain the role of chemo radiotherapy, the same authors utilized the linked SEER-Medicare database to study 1,137 Medicare beneficiaries with resected GBC who were treated between 1995 and 2005. Forty-one percent had node-positive disease, and 55 percent had T3/4 primary tumors. Overall, 126 patients received adjuvant chemotherapy, and an additional 126 received both chemotherapy and radiotherapy within six months of diagnosis, and thus, were considered to have received chemo radiotherapy. Treated patients tended to be younger and had higher T and N-stages. However, propensity-score weighting was used to balance all covariates between treated and untreated groups. Multivariate regression survival analysis was performed using several different modeling methods, and the best performing of these was used to construct a nomogram (available online) [29] that calculates the expected survival benefit from adjuvant chemotherapy and chemo radiotherapy. The authors concluded that patients with ≥ T2 or node-positive disease derived the greatest benefit from chemo radiotherapy and that in virtually all cases chemo radiotherapy outperformed chemotherapy alone [29] .
Neoadjuvant Therapy
Chemotherapy A large number of patients with GBC are locally advanced at diagnosis and as surgery remains the only curative option neo adjuvant strategy appears to be a reasonable option. Neoadjuvant chemotherapy has been evaluated in a retrospective study of 38 patients with locally advanced GBC treated at Tata Memorial Centre between Feb 2009 to May 2013 [30] . The objective of the study was to evaluate resectability rates in patients with locally advanced GBC (which was defined as GB mass infiltrating the liver >2 cm without porta hepatis/ vascular involvement, GB mass adherent to hepatic flexure and duodenum and, coeliac/gastrohepatic lymphadenopathy/ portocaval and peripancreatic nodes). Chemotherapy consisted Cisplatin 25 mg/m2 and Gemcitabine 1,000 mg/ m2 on D1 and D8 of 21d cycle, or Gemcitabine 1,000 mg/ m2 D1 and oxaliplatin 100 mg/m2 D2 every 2 weeks. Of all 38 patients, 33 patients were treated with Gem-P (25 oxaliplatin, 8 cisplatin; 1 cetuximab-Gem-P) based therapy and 5 patients received CTRT with gemcitabine 300 mg/m2 once a week. Response rate to neo adjuvant therapy was seen in 5 (13 %) complete response, 17 (45 %) partial response, 9 stable disease, 5 (13 %) progressive disease and was not assessed in 2 patients. Overall clinical benefit rate (CR+PR+SD) was 82 %. Of the 24 patients who underwent surgery, 21 (87 %) had curative surgery and 3 were not operable. This report of the use of neo adjuvant chemotherapy in patients with locally advanced GBC has encouraging results and prospective randomized studies are planned in future to validate the benefits seen.
Chemoradiotherapy
There is limited data in the treatment of GBC with chemo radiation in the neo adjuvant scenario. A few reports have included GBC along with pancreatic carcinoma, hence no meaningful conclusion can be drawn from such studies [31] .
Arextabala [32] et al. reported a prospective trial to evaluate the effect of neo adjuvant chemo-radiation on GBC. Patients with incidentally diagnosed GBC after surgery were included; a total of 23 patients were recruited. Chemotherapy was administered using 5-fluorouracil in continuous infusion for five days and radiotherapy upto 45 Gy. Overall survival of these patients was compared with 19 patients who did not undergo radiotherapy in the same institution. 14 patients underwent surgery; at a follow-up of 43.8 months five patients were still alive. It was concluded that chemo radiation had no significant positive effect on survival. On the contrary, the treated patients were reported to have an inferior survival.
An update of another study [33] was presented at the Indian chapter of International hepato pancreatico biliary association (IHPBA) in 2011. They reported results of 14 patients treated with concurrent chemo radiation with Gemcitabine 300 mg/ m2 every week. The data is presented in table 2 in comparison with other reports and a recent report of the efficiency of neo adjuvant chemotherapy in GBC [30] . Studies are needed to assess the resectability rate and information on downsizing post neo adjuvant therapy.
Treatment of Advanced Disease
Jaundice due to biliary obstruction is the presenting complaint in 30 to 60 percent of patients with GBC; the cause most often is infiltration of the common hepatic duct by tumor. [34] Stenting from a percutaneous or endoscopic approach is usually preferred over biliary bypass surgery. Drainage of just 30 percent of the liver parenchyma (can be accomplished by unilateral drainage of one lobe) is adequate to reduce jaundice and pruritus. Percutaneous and endoscopic methods of biliary drainage were compared in a trial in which 54 patients with GBC and a Bismuth type II or III biliary obstruction who were inoperable were randomly assigned to percutaneous trans hepatic biliary drainage or endoscopic stenting [35] . Successful drainage was achieved more frequently with percutaneous drainage (89 versus 41 percent), and cholangitis was a more frequent complication of endoscopic stenting (48 versus 11 percent). Stent occlusion rates (32 versus 39 percent) and survival (60 days in both groups) were not significantly different.
Chemotherapy
Reported response rates with chemotherapy in patients with GBC are in the range of 50 to 60 percent. There is limited data assessing the impact of treatment on overall survival. In the only randomized trial comparing chemotherapy (gemcitabine plus oxaliplatin [GEMOX] or 5-FU plus leucovorin) against supportive care alone in 81 patients with inoperable GBC, median OS was 4.5, 4.6, and 9.5 months in the supportive care, FU/leucovorin and GEMOX groups, respectively [36] .
In previous studies, response rates for 5-FU by itself or 5-FU-based combination treatment ranged from 0 to 34 percent, and median survival was less than six months. Capecitabine is an active agent in GBC. In a study of 63 patients with hepatobiliary carcinoma, which included eight with GBC, capecitabine (2,000 mg/m 2 daily for 14 of every 21 days) produced a response in four (50 percent) of the patients with GBC, two of which were complete [37] .
Infusional 5-FU has been combined with cisplatin in at least two trials. In one, 5-FU (1 gm/m 2 by continuous infusion daily for 5 days) along with cisplatin (100 mg/m 2 on day 2) caused partial remission in six patients (24 percent); one was a long-term survivor after administration of additional local therapy. Median survival for patients with GBC was 11.5 months. [38] In another report, ECF regimen as compared to 5-FU along with leucovorin and etoposide (response rate 19 versus 15 percent, median overall survival nine against 12 months, respectively). ECF was associated with significantly less acute toxicity [39] . In another trial, capecitabine (1,000 mg/m 2 twice daily on days 1 to 14) along with oxaliplatin (130 mg/m 2 over 1 hour on day 1) was administered to 65 patients with biliary tract tumors, 27 with GBC, the rest were cholangiocarcinoma [40] . Of the 27 patients with GBC, there was one complete and seven partial responders; another nine had stable disease (total disease control rate 63 percent). The median survival was 11.3 months.
Gemcitabine in combination with Capecitabine is also active. Gemcitabine (1,000 mg/m 2 on days 1 and 8) plus capecitabine (650 mg/m2 twice daily for 14 of every 21 day cycle) was well tolerated. There were 22 objective responses (three complete), which were seen. The median progressionfree and overall survival rates were 6.2 and 12.7 months, respectively. [41] In another study of 24 patients with GBC, treated with the same doses of gemcitabine but a higher dose of capecitabine (1,000 mg/m 2 twice daily for 14 of every 21 days), one-third had a partial response, and the median survival was 16 months [42] .
The superiority of gemcitabine along with cisplatin over gemcitabine alone was shown in the multicenter ABC-02 trial, in which a total of 410 patients with locally advanced (25 percent) or metastatic bile duct (n=242), gallbladder (n=148) or ampullary (n=20) carcinoma were randomly assigned to six courses of cisplatin (25 mg/m 2 ) followed by gemcitabine (1,000 mg/m 2 ) on days 1 and 8, every 21 days, or gemcitabine alone (1,000 mg/m 2 days 1, 8, 15, every 28 days) [8] . At a median follow-up of 8.2 months, median overall survival was much greater with combination therapy (11.7 versus 8.1 months), as was median PFS (8 versus 5 months). A meta-analysis combining the data from the two available randomized trial in biliary cancer was reported recently [43] . Gemcitabine in combination with cisplatin showed a significant improvement in PFS [hazard ratio (HR)=0.64, 95 % confidence interval (CI) 0.53-0.76, P < 0.001] and OS (HR = 0.65, 95 % CI 0.54-0.78, P<0.001) over gemcitabine alone. This effect was most marked in patients with good performance status. Improvement in progression free and OS was seen both in cholangiocarcinomas and GBC. The subgroups least likely to benefit included patients with ampullary tumours and poor performance status.
Gemcitabine/cisplatin combination has not been compared to other gemcitabine combinations (eg, with capecitabine, leucovorin-modulated 5-FU, or oxaliplatin) or capecitabine along with oxaliplatin in randomized trials.
Oxaliplatin and Gemcitabine was studied in a phase II study, the response rate was about 36 percent with 26 % stable disease. The median survival duration was 15.4 months using every 2 weekly gemcitabine (1,000 mg/m 2 day 1) and oxaliplatin (100 mg/m 2 day 2) in a group of 33 previously untreated patients with advanced biliary cancer (19 with GBC) with a good performance status, and a serum bilirubin level <2.5 times normal. [44] Table 3 summarizes some of the available studies of chemotherapy in advanced biliary cancer.
Targeted Therapy
Some reports suggest benefit from blockade of the epidermal growth factor receptor (EGFR) by the oral tyrosine kinase inhibitor erlotinib. [45] In one report, 42 patients with advanced biliary cancer (not stratified according to primary site), 57 percent had received prior chemotherapy, received erlotinib (150 mg daily). There were three partial responders (two with documented expression of EGFR) and seven patients remained progression-free at six months. All responders had mild (grade 1 or 2) skin toxicity [45] .
The efficacy of bevacizumab, a monoclonal antibody targeting VEGF, along with erlotinib was addressed in a multinational phase II study [46] . Fifty-three patients with advanced cholangiocarcinoma (n = 43) or GBC (n =10) received bevacizumab (5 mg/kg every two weeks) along with erlotinib (150 mg once daily). Nine patients achieved PR, which was sustained for more than four weeks in six patients (12 percent), with a median response duration of 8.4 months. Table 4 summarizes some of the available studies using targeted therapy in advanced biliary cancer.
Conclusion
Early detection and radical resection for GBC offers the only chance of cure. Unfortunately due to delay in presentation most patients have nodal or distant metastasis and prognosis is poor even after complete resection. Studies of gallbladder cancers alone have reported worse outcomes compared to studies including cholangiocarcinoma. Due to its varied epidemiology and aggressive behaviour GBC has to be studied exclusively and separately from other biliary cancers. The role of radiotherapy in incompletely operated GBC needs to be addressed in a randomized trial. Chemotherapy in the neo adjuvant or adjuvant setting has to be studied in well designed randomized trials to establish optimal treatment. The BILCAP [47] study which is randomizing patients with resected biliary tract cancers to oral capecitabine versus observation has completed accrual and the results are awaited. Until the trial results are available, watch and wait remains the strategy for resected GBC. Targeted therapy has not made any major impact in this disease and should only be offered to patients in well designed clinical trials. In advanced disease combination of gemcitabine along with platinum is the current standard of care in patients who can tolerate cytotoxic chemotherapy.
